ARRY Related Analyst Ratings
-
Piper Jaffray Upgrades Array BioPharma (ARRY) to Overweight
-
UPDATE: Leerink Swann Upgrades Array BioPharma (ARRY) to Outperform; Exciting Data Help Leverage to MEK Inhibitors
-
Jefferies Maintains a 'Buy' on Array BioPharma (ARRY); Narrowing Loss; Phase 2 Data Driving Further Upside
-
Jefferies Discusses Array BioPharma (ARRY) After Detailed Selumetinib Ph2 Data in NSCLC
-
BMO Starts Biotech Stocks: AMGN, HGSI, REGN, CELG at Outperform, AMLN, GILD, ARNA at Market Perform, BIIB at Underperform
-
Barclays Reiterates an 'Overweight' on Array BioPharma (ARRY); Reports FY2Q11, Data for MEK inhibitors in 2011
-
UPDATE - UBS Upgrades Array BioPharma (ARRY) to Buy; Valuation Call
-
UBS Upgrades Array BioPharma (ARRY) to Buy
-
Leerink Swann Lifts Price Target On Array BioPharma (ARRY) to $4
-
Array Bio (ARRY) Trading Lower as UBS Downgrades from Buy to Neutral; Shares Down Over 5%
-
UBS Downgrades Array BioPharma (ARRY) to Neutral
-
UBS Upgrades Array BioPharma (ARRY) to Buy
-
UBS Downgrades Array Biopharma (ARRY) to Neutral
-
Leerink Swann Downgrades Array Biopharma (ARRY) to Market Perform; Phase II trial of ARRY-162 Results Poor
-
Baird Downgrades Array BioPharma (ARRY) to Neutral
-
Boenning & Scattergood Initiates Coverage on Array BioPharma (ARRY)
-
Barclays Gets Bullish On US Biotechnology Sector (BBH)
-
Susquehanna Initiates Coverage on Array BioPharma (ARRY) with a Positive
-
Baird Reiterates Outperform on Array BioPharma (ARRY)
-
William Blair Starts Array BioPharma (ARRY) at Outperform
-
Morgan Joseph Starts Array BioPharma (ARRY) at Buy
-
Lehman Brothers Starts Array Biopharma (ARRY) at Overweight
-
Rodman & Renshaw Starts Array Biopharma (ARRY) at Market Outperform
-
JP Morgan Starts Array Biopharma (ARRY) at Overweight
-
ThinkEquity Starts Array Biopharma (ARRY) at Buy
-
Piper Jaffray names Array BioPharma (ARRY) a new Top Pick for 2007
-
Oppenheimer Starts Array BioPharma (ARRY) at Buy
-
WR Hambrecht Raises Price Target on Array Biopharma (ARRY) to $17
-
Banc of America Starts Array BioPharma (ARRY) at Buy
-
Robert W Baird Starts Array Biopharma (ARRY) at Outperform
-
Piper Jaffray Raises Price Target on Array BioPharma (ARRY)
-
CE Unterberg Towbin Issues Q3 Top Picks
-
Jefferies & Co Initiates Coverage on Array BioPharma (ARRY) with a Buy
-
CE Unterberg Starts Array Biopharma (ARRY) at Buy
-
WR Hambrecht comments on Array Biopharma (ARRY)
-
Merriman Curhan Starts ARRY at Buy
-
WR Hambrecht Starts ARRY at Buy
-
ARRY started at Buy at UBS; $12 price tgt
Back to ARRY Stock Lookup
